Cytogenetic remissions in high-risk myelodysplastic syndrome: Results in 124 patients treated with low-dose 5-aza-2 '-deoxycytidine (Decitabine), a DNA methylation inhibitor.

Lubbert, M., Ferrant, A., Wijermans, P., Kunzmann, R., Verhoef, G., Bosly, A., Ravoet, C., & André, M. (2000). Cytogenetic remissions in high-risk myelodysplastic syndrome: Results in 124 patients treated with low-dose 5-aza-2 ’-deoxycytidine (Decitabine), a DNA methylation inhibitor. Blood, 96(11), 546A-+. (Original work published 2000)